Creative Commons source reading · ALS and frontotemporal degeneration
PERK inhibition prevents tau-mediated neurodegeneration in a mouse model of frontotemporal dementia.
Helois Radford; Julie A Moreno; Nicholas Verity; Mark Halliday; Giovanna R Mallucci
Originally published in Acta neuropathologica · 2015-10-08
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
The PERK-eIF2α branch of the Unfolded Protein Response (UPR) mediates the transient shutdown of translation in response to rising levels of misfolded proteins in the endoplasmic reticulum. PERK and eIF2α activation are increasingly recognised in postmortem analyses of patients with neurodegenerative disorders, including Alzheimer's disease, the tauopathies and prion disorders. These are all characterised by the accumulation of misfolded disease-specific proteins in the brain in association with specific patterns of neuronal loss, but the role of UPR activation in their pathogenesis is unclear. In prion-diseased mice, overactivation of PERK-P/eIF2α-P signalling results in the sustained reduction in global protein synthesis, leading to synaptic failure, neuronal loss and clinical disease. Critically, restoring vital neuronal protein synthesis rates by inhibiting the PERK-eIF2α pathway, both genetically and pharmacologically, prevents prion neurodegeneration downstream of misfolded prion protein accumulation.
Editorial reading guide
- Was the evidence cross-sectional, longitudinal or experimental?
- How did the authors account for age, disease stage and differences among participants?
